Indeed, a blockade of mTOR with N-acetylcysteine, Rapamycin and Sirolimus, another mTOR inhibitor, has shown promising results in both pre-clinical and clinical settings since the activity of mTOR has been found to be increased in lupus T cells [29,30,31,32]. This evidence concerns the gene MTOR and systemic lupus erythematosus.